Case Study: Oramed rescues its oral insulin trial with PhaseV Response Optimizer

PhaseV Causal-ML Identifies Key Responders to Investigational Oral Insulin Treatment

Oramed faced a significant challenge when its Phase III trial for an oral insulin candidate failed to meet its primary endpoint. Without a clear understanding of which patient subgroups might respond to the treatment, the future of their program was at risk. They turned to the vendor PhaseV for a solution using its Response Optimizer service.

PhaseV applied its Response Optimizer HTE Pipeline to analyze the clinical trial data. This analysis identified specific patient subgroups, characterized by factors like BMI and age, that showed a significant response to the treatment. As a result of these findings, PhaseV's work enabled Oramed to re-initiate a targeted Phase III trial under an amended protocol, rescuing the program.

Oramed